Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Paraneoplastic syndromes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Paraneoplastic syndromes. Displaying page 1 of 1.
    EudraCT Number: 2008-000793-20 Sponsor Protocol Number: PNS2008-01 Start Date*: 2008-05-05
    Sponsor Name:Erasmus MC [...]
    1. Erasmus MC
    2.
    Full Title: Sirolimus (Rapamune®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes
    Medical condition: Paraneoplastic Neurological Syndromes associated with anti-Hu antibodies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014619 Encephalomyelitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000675-13 Sponsor Protocol Number: PNS2014-01 Start Date*: 2016-02-03
    Sponsor Name:Erasmus University Medical Center
    Full Title: Natalizumab (Tysabri®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes
    Medical condition: Anti-Hu associated paraneoplastic neurological syndromes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000177-23 Sponsor Protocol Number: P170930J Start Date*: 2021-04-13
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: IMMUNOTHERAPY WITH INTRAVENOUS IMMUNOGLOBULINS, CYCLOPHOSPHAMIDE AND METHYLPREDNISOLONE IN PATIENTS WITH PARANOPLASTIC SENSITIVE NEURONOPATHIES WITH ANTI-HU ANTIBODIES
    Medical condition: Paraneoplastic Neurological Syndromes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003090-42 Sponsor Protocol Number: 1417-LCG Start Date*: 2018-06-18
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
    Medical condition: Extended disease Small Cell Lung Cancer (ED-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001146-17 Sponsor Protocol Number: ML41118 Start Date*: 2019-07-16
    Sponsor Name:ROCHE SPA
    Full Title: A PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) IN COMBINATION WITH CARBOPLATIN PLUS ETOPOSIDE TO INVESTIGATE SAFETY AND EFFICACY IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE ...
    Medical condition: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (es-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001256-39 Sponsor Protocol Number: CA184-041 Start Date*: 2008-02-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind, Parallel, Three Arm, Multicenter, Phase II Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Taxol®/Paraplatin® (Paclitaxel/Carbopl...
    Medical condition: Study Population: Men and women who are ≥ 18 years old with histologically or cytologically confirmed lung cancer (Stage IIIb/IV NSCLC or extensive stage SCLC) with ECOG performance ≤ 1, who have m...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB PT
    9.1 10029522 Non-small cell lung cancer stage IV PT
    9.1 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:40:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA